A therapeutic trial of anti-lymphocytic globulin in acute ulcerative colitis.
The results of the preliminary part of a controlled therapeutic trial of antilymphocytic globulin (ALG) in severe acute ulcerative colitis are presented. 10 patients have been studied in this part of the trial, 5 receiving standard treatment with corticosteroids, and 5 receiving ALG, in a dose of 1 g daily for 5 days, in addition to the standard treatment. No difference has been observed in the clinical course of the patients in the two groups. A continuation of the trial is in progress, using ALG in a larger dose (2 g daily for 5 days).